A 45-year-old Japanese womanwith multiple sclerosis (MS) manifested hypersomnia in a relapse of MS.
Introduction
Hypocretin (also knownas orexin) is a newly discovered hypothalamic neuropeptide (1, 2) , whose function is relevant to the arousal stimulating system (3) . Previous studies have revealed that the hypocretin-1 (orexin-A) level in cerebrospinal fluid (CSF) is decreased in narcolepsy (4) and in a few other conditions showing hypersomnia, such as diencephalic stroke (5) and post resection of tumor in the hypothalamus (6) . Although hypersomnia is a rare complication in multiple sclerosis (MS) (7) , the prevalence of sleep attack is significantly high in comparison with normal subjects (8) . Wepresent a patient with MS, who developed hypersomnia accompanied by bilateral hypothalamic lesions and a decreased CSFhypocretin-1 concentration. After corticosteroid treatment, she recovered from the hypersomnia, the left hypothalamic lesion disappeared, and the CSF hypocretin-1 level returned to normal. This is the first case of MSwith hypothalamic lesions, suggesting a causal relationship between hypersomnia and decreased CSF hypocretin-1 level.
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Case Report
A 45-year-old Japanese womanwas admitted to the hospital because of hypersomnia. At age 41, she developed oneand-a-half syndrome with right gaze palsy. Total protein in CSF was 35 mg/dl (normal range: less than 40 mg/dl), and myelin basic protein (MBP) in CSF was 7.5 ng/ml (normal range: less than 4.0 ng/ml). Brain magnetic resonance image Hypersomnia and Low CSF Hypocretin-1 in MS hypothalamic lesion (Fig. 2C) , but the right hypothalamic lesion remained.
Discussion
Onadmission, our patient presented with a hypersomnolent state, but she did not have clinical signs of narcolepsy or paradoxical alpha blocking in EEC The hypersomnolent state in our patient was considered a consciousness disturbance, resulting from dysfunction of the ascending arousal reticular system, rather than a disturbance of the switching system between wakefulness and sleep, as in narcolepsy. The optic chiasm, brainstem, cerebellum and spinal cord are commonly involved in MS (7) . Although the hypothalamus is abundant in grey matter and it seems to be spared in MS, pathological investigation has demonstrated that almost all MSpatients have hypothalamic demyelinated lesions, and 18% of MS patients have hypercellular lesions in the hypothalamic grey matter (1 1). In addition, the left hypothalamic lesion in our patient was M-PSLpulse responsive. According to these findings, the hypothalamic lesions of our patient were assumed to be demyelinated and inflammatory lesions caused by MS.
It has been demonstrated that hypothalamic hypocretincontaining neurons project to and stimulate the ascending arousal reticular system, which includes the Raphe nucleus, locus ceruleus and tuberomammillary nucleus (3). Hypocretin has been indicated to be a key peptide in an awakening system. This indication was confirmed by recent reports demonstrating that orexin knockout mice (12) and dogs with disruption of the hypocretin receptor 2 gene (13) exhibited human narcolepsy-like phenotype. It is, therefore, suggested that MS lesions in the hypothalamic areas decreased CSF hypocretin-1 level and caused hypersomnia in our patient. It is interesting that the hypersomnia did not appear until the hypothalamic areas were bilaterally involved and that the CSFhypocretin-1 level returned to normal after remission of the unilateral hypothalamic lesion in our patient. These findings suggest that the hypothalamic system on one side can maintain wakefulness and CSF hypocretin-1 level.
